Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol vs Febuxostat in MAFLD
NCT05474560Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of allopurinol, febuxostat in metabolic associated fatty liver disease (MAFLD), sponsored by Ain Shams University. Started Jan 2022; status: completed.
02
Drugs
allopurinolfebuxostat
03
Conditions
metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT05474560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05474560.